Hmdb loader
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 14:13:49 UTC
Update Date2021-09-26 23:09:02 UTC
HMDB IDHMDB0254782
Secondary Accession NumbersNone
Metabolite Identification
Common NameAdavosertib
DescriptionMK-1775 belongs to the class of organic compounds known as phenylpiperazines. Phenylpiperazines are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. MK-1775 is a very strong basic compound (based on its pKa). University of Michigan researchers are as of 2019 planning a phase 2 study. It is being investigated as a treatment for pancreatic cancer with phase 1 trial. Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca. This compound has been identified in human blood as reported by (PMID: 31557052 ). Adavosertib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Adavosertib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
2-Allyl-1-(6-(2-hydroxy-2-propanyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-1,2-dihydro-3H-pyrazolo(3,4-D)pyrimidin-3-oneMeSH
Chemical FormulaC27H32N8O2
Average Molecular Weight500.607
Monoisotopic Molecular Weight500.264822302
IUPAC Name1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-3-one
Traditional Name1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-2-(prop-2-en-1-yl)pyrazolo[3,4-d]pyrimidin-3-one
CAS Registry NumberNot Available
SMILES
CN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C1
InChI Identifier
InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
InChI KeyBKWJAKQVGHWELA-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as phenylpiperazines. Phenylpiperazines are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • Phenylpiperazine
  • N-arylpiperazine
  • 2-pyrazolylpyridine
  • Pyrazolopyrimidine
  • Pyrazolo[3,4-d]pyrimidine
  • Tertiary aliphatic/aromatic amine
  • Dialkylarylamine
  • Aniline or substituted anilines
  • Aminopyrimidine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Benzenoid
  • Pyrazolinone
  • Pyridine
  • Monocyclic benzene moiety
  • Pyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Azole
  • Pyrazole
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Lactam
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organopnictogen compound
  • Alcohol
  • Aromatic alcohol
  • Organic oxide
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP3.3ALOGPS
logP3.17ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.69ChemAxon
pKa (Strongest Basic)7.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area100.96 ŲChemAxon
Rotatable Bond Count7ChemAxon
Refractivity155.95 m³·mol⁻¹ChemAxon
Polarizability54.19 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityYesChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+215.68530932474
DeepCCS[M-H]-213.2930932474
DeepCCS[M-2H]-246.17430932474
DeepCCS[M+Na]+221.59830932474
AllCCS[M+H]+221.732859911
AllCCS[M+H-H2O]+219.832859911
AllCCS[M+NH4]+223.332859911
AllCCS[M+Na]+223.832859911
AllCCS[M-H]-216.632859911
AllCCS[M+Na-2H]-217.532859911
AllCCS[M+HCOO]-218.632859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
AdavosertibCN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C14626.7Standard polar33892256
AdavosertibCN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C14024.8Standard non polar33892256
AdavosertibCN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C14518.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Adavosertib,2TMS,isomer #1C=CCN1C(=O)C2=CN=C(N(C3=CC=C(N4CCN(C)CC4)C=C3)[Si](C)(C)C)N=C2N1C1=CC=CC(C(C)(C)O[Si](C)(C)C)=N14320.3Semi standard non polar33892256
Adavosertib,2TMS,isomer #1C=CCN1C(=O)C2=CN=C(N(C3=CC=C(N4CCN(C)CC4)C=C3)[Si](C)(C)C)N=C2N1C1=CC=CC(C(C)(C)O[Si](C)(C)C)=N13841.5Standard non polar33892256
Adavosertib,2TMS,isomer #1C=CCN1C(=O)C2=CN=C(N(C3=CC=C(N4CCN(C)CC4)C=C3)[Si](C)(C)C)N=C2N1C1=CC=CC(C(C)(C)O[Si](C)(C)C)=N15333.7Standard polar33892256
Adavosertib,2TBDMS,isomer #1C=CCN1C(=O)C2=CN=C(N(C3=CC=C(N4CCN(C)CC4)C=C3)[Si](C)(C)C(C)(C)C)N=C2N1C1=CC=CC(C(C)(C)O[Si](C)(C)C(C)(C)C)=N14668.3Semi standard non polar33892256
Adavosertib,2TBDMS,isomer #1C=CCN1C(=O)C2=CN=C(N(C3=CC=C(N4CCN(C)CC4)C=C3)[Si](C)(C)C(C)(C)C)N=C2N1C1=CC=CC(C(C)(C)O[Si](C)(C)C(C)(C)C)=N14187.1Standard non polar33892256
Adavosertib,2TBDMS,isomer #1C=CCN1C(=O)C2=CN=C(N(C3=CC=C(N4CCN(C)CC4)C=C3)[Si](C)(C)C(C)(C)C)N=C2N1C1=CC=CC(C(C)(C)O[Si](C)(C)C(C)(C)C)=N15327.5Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Adavosertib GC-MS (TMS_1_1) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Adavosertib GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Adavosertib GC-MS (TBDMS_1_1) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Adavosertib GC-MS (TBDMS_1_2) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 10V, Positive-QTOFsplash10-0ue9-0001940000-5b83b5864f697d7505292017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 20V, Positive-QTOFsplash10-0006-8102910000-39a8bbc2d913e0e4d1732017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 40V, Positive-QTOFsplash10-0006-8425900000-eae66f73c2cdd34b9e782017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 10V, Negative-QTOFsplash10-0002-0000900000-2f1d9d66387e2fc60ab42017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 20V, Negative-QTOFsplash10-0aos-0021900000-9aa18f6037de276afc642017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 40V, Negative-QTOFsplash10-0296-7674900000-5e7e793c9f9eb5c15f132017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 10V, Negative-QTOFsplash10-0005-0000900000-f153b55df66bfd40cbdc2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 20V, Negative-QTOFsplash10-0a4i-0000900000-615648cb2d70b0db18132021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 40V, Negative-QTOFsplash10-0159-0331900000-7e18c43e0aa7d96a20502021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 10V, Positive-QTOFsplash10-0f89-0000980000-87ddff9e3dbe8821a7532021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 20V, Positive-QTOFsplash10-0k96-0000930000-d9bd413acb9b9b4a4d202021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Adavosertib 40V, Positive-QTOFsplash10-03dl-0000900000-a0500025763cdd5d7ba02021-10-12Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB11740
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkAdavosertib
METLIN IDNot Available
PubChem Compound24856436
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]